Oppenheimer Downgrades Snap to Perform

Oppenheimer analyst Jason Helfstein downgrades Snap (NYSE:SNAP) from Outperform to Perform.

byBenzinga Newsdesk

July 22, 2022

1 minute read

Oppenheimer analyst Jason Helfstein downgrades Snap (NYSE:SNAP) from Outperform to Perform.

CRISPR Therapeutics Announces Oral Presentation Of New Clinical Data On Anti-CD70 Allogeneic CAR-T Therapy CTX130 For Patients With T-Cell Lymphoma At The Annual European Hematology Association 2022 Hybrid Congress

By Benzinga Newsdesk

May 12, 10:34 AM

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid

CRSP

Cognition Therapeutics Is Recruiting For Lewy Body Dementia Phase 2 SHIMMER Trial In Seventeen Research Sites Across The U.S.

By Benzinga Newsdesk

October 12, 8:05 AM

Lewy Body Dementia (LBD) patients are actively being recruited by Cognition Therapeutics, Inc. (NASDAQ:CGTX) and its clinical partners for the SHIMMER Phase 2 trial of their CT1812 oral drug therapy at 17

CGTX

Citigroup Downgrades Consolidated Comms Hldgs to Sell, Raises Price Target to $8

By Benzinga Newsdesk

June 3, 8:22 AM

Citigroup analyst Michael Rollins downgrades Consolidated Comms Hldgs (NASDAQ:CNSL) from Neutral to Sell and raises the price target from $7.5 to $8.

CNSL

Credit Suisse Maintains Outperform on Williams Companies, Raises Price Target to $33

By Benzinga Newsdesk

November 11, 8:49 AM

Credit Suisse analyst Spiro Dounis maintains Williams Companies (NYSE:WMB) with a Outperform and raises the price target from $30 to $33.

WMB

Oppenheimer Downgrades Snap to Perform

Related Posts

CRISPR Therapeutics Announces Oral Presentation Of New Clinical Data On Anti-CD70 Allogeneic CAR-T Therapy CTX130 For Patients With T-Cell Lymphoma At The Annual European Hematology Association 2022 Hybrid Congress

Cognition Therapeutics Is Recruiting For Lewy Body Dementia Phase 2 SHIMMER Trial In Seventeen Research Sites Across The U.S.

Citigroup Downgrades Consolidated Comms Hldgs to Sell, Raises Price Target to $8

Credit Suisse Maintains Outperform on Williams Companies, Raises Price Target to $33